Mårten Fernö
111 – 120 of 258
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
2010) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 23. p.251-259(
- Contribution to journal › Article
-
Mark
Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.
(
- Contribution to journal › Article
-
Mark
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
(
- Contribution to journal › Article
-
Mark
Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1.
(
- Contribution to journal › Article
-
Mark
Modeling Prognostic Markers in Breast Cancer — Are We Using Them the Optimal Way?
(
- Contribution to journal › Published meeting abstract
-
Mark
Prediction of outcome after diagnosis of metachronous contralateral breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
AIB1 is a predictive factor for tamoxifen response in premenopausal women.
(
- Contribution to journal › Article
- 2009
-
Mark
Cyclin B1 Is an Independent Prognostic Proliferation Marker with a High Reproducibility in a Population-Based Lymph Node Negative Breast Cancer Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer
(
- Contribution to journal › Published meeting abstract